Discovery Labs shares dive on FDA delay

Investors took a big bite out of Discovery Laboratories' stock value this morning after the developer announced that it would delay a response to the FDA on its experimental lung drug for infants by two months. Back in early May, the company had said it would only take six to eight weeks to formulate a response to the FDA's approvable letter for Surfaxin. But officials say now that they won't hand back a reply until September.

That's not what investors wanted to hear. Shares plunged 28 percent on the news. Discovery's announcement also includes its belief that the FDA will classify its response as a Class 1 resubmission with a 60-day target review period.

- check out the release
- read the AP report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.